Innova Captab Limited · NSE:INNOVACAP
Innova Captab — Q4 FY25 Earnings Presentation
34 slides from Innova Captab's earnings presentation, May 19, 2025
Slide 1: Intimation of Investor Presentation to stock exchanges
INNOVA CAPTAB LIMITED 1281/1, Hilltop Industrial Estate, Near EPIP, Phase-I, Jharmajri, Baddi, Dist. Solan (H.P.)-173205 India. Phone: +91-1795-650820 May 19, 2025 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor Dalal Street, Mumbai –
Slide 2: Investor Presentation – 19th May 2025
INVESTOR PRESENTATION – 19th May 2025 1
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Innova Captab Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: Company Overview
Dg ac all = Br a5 > a &) Company Overview “(e) CAPTAB
Slide 5: One of the leading Integrated Pharmaceutical Player
One of the leading Integrated Pharmaceutical Player Business Areas Contract Development and 200+ 3,300+ Serving Top Manufacturing (CDMO) CDMO Customers CDMO Products Pharmaceutical Companies in India Comprehensive Suit of 2.2 lakh+ Strong In-house sales team of 350+ Domestic Branded Generics 750 + P
Slide 6: With State-of-the-Art Manufacturing Facilities
With State-of-the-Art Manufacturing Facilities Kathua, Jammu [4 Blocks] 9 Third Largest Manufacturing Blocks Finished Tablet and Capsule Upcoming R&D Manufacturing Capacity in India Baddi, Himachal Pradesh (2 Units) [3 Blocks] 3 Baddi |1 Dehradun |1 Taloja | 4 Facility in Panchkula, amongst the peer
Slide 7: Journey of Achieving Major Milestones
Journey of Achieving Major Milestones Foundation International GMP Certification Further Expansion Acquisition of Sharon • Acquisition of Sharon, through the • Innova Captab began its journey • Received GMP Certificate for • Further expanded the G block to Corporate Insolvency Resolution in 2006 wit
Slide 8: Q4 & FY25 Performance Highlights
Q4 & FY25 Performance Highlights 7
Slide 9: MD's Commentary
MD’s Commentary We ended the year on a strong note, with all business areas performing in line with expectations. Strategic decisions taken over recent years are now delivering clear, measurable results—reflected in both our financial and operational performance. This momentum underscores the streng
Slide 10: Quarterly Financial Performance Highlights – Revenue
Quarterly Financial Performance Highlights – Revenue Revenue (₹ Crores) Revenue from Operations registered robust growth of 20% year-on- +20% year, reaching ₹ 314.7 crores in Q4 FY25, driven by strong 314.7 performance across all business areas 262.6 • CDMO business posted 12% YoY growth to ₹ 154.8
Slide 11: Quarterly Financial Performance Highlights - Profitability
Quarterly Financial Performance Highlights - Profitability EBITDA (₹ Crores) 16.7% 16.2% Margin +17% 51.1 43.8 • Overall EBITDA registered stellar growth of 17% on YoY basis, reaching ₹ 51.1 crores • EBITDA margins were 16.2% Q4 FY24 Q4 FY25 • PAT rose by 3% year-over-year to ₹ 29.6 crores after abs
Slide 12: Yearly Operational Performance Highlights
Yearly Operational Performance Highlights FY24 FY25 Total CDMO Customers 190+ 200+ Number of CDMO Product Offerings 2,900+ 3,300+ Product Offerings in Domestic Branded Generics 600+ 750+ Touchpoints in Domestic Branded Generics 150,000+ 220,000+ Presence in International Markets 25+ 30 11 1 Crisil R
Slide 13: Yearly Financial Performance Highlights – Revenue
Yearly Financial Performance Highlights – Revenue Revenue (₹ Crores) +15% Revenue from Operations grew 15% to ₹ 1,243.7 crores led by 1,243.7 volume growth across business areas 1,081.3 • CDMO business grew 6% on YoY basis to ₹ 659.9 crores • Domestic branded generics business registered YoY growth
Slide 14: Yearly Financial Performance Highlights - Profitability
Yearly Financial Performance Highlights - Profitability EBITDA (₹ Crores) 15.4% 15.9% Margin +19% 198.2 166.9 • EBITDA registered robust growth of 19% to ₹ 198.2 crores • EBITDA margin increased by 50 basis points to 15.9% FY24 FY25 • PAT witnessed strong growth of 36% to ₹ 128.3 crores driven by hi
Slide 15: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit and Loss (₹ crores) Q4 FY25 Q4 FY24 YoY Growth FY25 FY24 YoY Growth Revenue from Operations 314.7 262.6 19.8% 1,243.7 1,081.3 15.0% Other Income 3.4 5.7 12.0 12.5 Total Income 318.1 268.3 18.6% 1,255.7 1,093.8 14.8% Cost of Material Consumed 198.0 168.3 81
Slide 16: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (₹ crores) Mar 2025 Mar 2024 Equity & Liabilities (₹ crores) Mar 2025 Mar 2024 Non - Current Assets 877.3 741.1 Total Equity 959.4 830.9 Property, plant and equipment 766.9 291.6 Share Capital 57.2 57.2 Right of use assets 45.5 48.7 Other Equity 902.2 773.7 Capital
Slide 17: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (₹ crores) FY25 FY24 Net Profit Before Tax 171.0 129.5 Adjustments for: Non -Cash Items / Other Investment or Financial Items (31.3) (37.3) Operating profit before working capital changes 202.3 166.8 Changes in working capital (114.4) 7.3 Cash generated f
Slide 18: Key Strengths
Dg a al > GP BHSS) Key Strengths “(e) CAPTAB
Slide 19: Key Strengths
Key Strengths 01 02 03 Relentless Expansion Customer Centric Diversified Business of Manufacturing Approach Areas Capacities 04 05 06 R&D Centric Experienced Consistent Financial Organization Promoters and Board Performance of Directors 18
Slide 20: Relentless Expansion of Manufacturing Capabilities (1/3)
Relentless Expansion of Manufacturing Capabilities (1/3) Annualized Installed Capacity Jammu Plant Tablets 10,679 mn Sharon Capsules 1,440 mn Dry Powder Tablets and 547 mn 2,012 mn Injections Baddi Plant Capsules Dry Syrups 311 mn Tablets 8,192 mn 365 metric BFS* (Large Volume API Capsules 2,472 mn
Slide 21: Jammu Plant Commercialised (2/3)
Jammu Plant Commercialised (2/3) 4 New Blocks Dosages Offered Fiscal Benefits o Cephalosporin o Oral Solid Dosages Poised to benefit from Central Government's 'New Central Sector Total Capital o Penicillin* o Dry Powder Injectables Scheme’ : Investment of o Dry Syrup • GST-linked incentive of 300% o
Slide 22: Growth Fueled by Capacity Expansion (3/3)
Growth Fueled by Capacity Expansion (3/3) Baddi Plant Dehradun | Taloja Plant Greenfield project at Jammu 15% - 20% 15% - 20% 20%-30% 70% - 75% 40%-50% 70%-75% 70% - 75% Capacity 50% - 55% Utilization 50% - 60% FY25 Un-utilized Capacity Optimum Utilization Commenced Ramp up in Further Optimum in com
Slide 23: Diversified Business Areas
2. Diversified Business Areas FY25 Revenue mix Offer multiple dosage forms Including- 3,300+ CDMO 1. CDMO Oral solids | Oral Liquids | Dry syrups | Dry powder injectables | Products 200+ Customers 53% Ointments | Large and Small Volume Parenterals | Respules • Our branded generics business focuses o
Slide 24: Customer Centric Approach
3. Customer Centric Approach Number of CDMO Customers Number of CDMO Products 216 3,300 193 2,900 200+ 174 182 2,400 CDMO Customers 2,181 119 1,066 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Serving Top Indian Revenue from Customers with >5 years Pharmaceutical companies Revenue from CDMO (₹
Slide 25: R&D Centric Organisation
4. R&D Centric Organisation Robust Research and Development 01 Dedicated R&D facility and pilot equipment located in Baddi, Himachal Pradesh, recognized by DSIR for its in-house R&D work. State-of-the-art facility equipped with comprehensive suite of necessary tools for developing solid oral and liq
Slide 26: Experienced Promoters and Board of Directors
5. Experienced Promoters and Board of Directors Manoj Kumar Lohariwala Vinay Lohariwala Jayant Vasudeo Rao Archit Aggarwal Chairman & Whole-time Director Managing Director Whole-time Director Non-Executive Director ▪ Bachelor’s in Commerce from Mohta ▪ Bachelor’s in Engineering (Mechanical) ▪ Bachel
Slide 27: Consistent Financial Performance
6. Consistent Financial Performance Revenue from Operations EBITDA (₹ crores) PAT (₹ crores) (₹ crores) 13.6% 12.4% 13.3% 15.4% 15.9% 8.4% 8.0% 7.3% 8.7% 10.3% Margin +32% 1,244 1,081 198 926 +37% 167 801 128 +38% 123 99 94 411 64 68 56 35 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22
Slide 28: Growth Strategies
Dg ac all = Br a5 > a &) Growth Strategies “(e) CAPTAB
Slide 29: Multiple Levers for Growth
Multiple Levers for Growth Capitalizing on Enhanced Manufacturing o Increased manufacturing capacity with new product offerings and dosage forms will fuel growth for both 01. Capabilities CDMO and branded generics business o To expand business with existing customers while also cultivating new relat
Slide 30: Historical Financial Performance
Historical Financial Performance 29
Slide 31: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit and Loss (₹ crores) FY25 FY24 FY23 FY22 FY21 Revenue from Operations 1,243.7 1,081.3 926.4 800.5 410.7 Other Income 12.0 12.5 9.2 2.9 1.4 Total Revenue 1,255.7 1,093.8 935.6 803.4 412.0 Cost of Materials Consumed 814.1 728.3 691.6 617.9 310.7 Employee Cost
Slide 32: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (₹ crores) FY25 FY24 FY23 FY22 FY21 Equity & Liabilities (₹ crores) FY25 FY24 FY23 FY22 FY21 Non - Current Assets 877.3 741.1 261.9 196.4 99.1 Total Equity 959.4 830.9 276.5 208.6 144.8 Property, plant and equipment 766.9 291.6 150.1 156.6 76.4 Share Capital 57.2 57
Slide 33: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (₹ crores) FY25 FY24 FY23 FY22 FY21 Net Profit Before Tax 171.0 129.5 91.8 85.7 46.3 Adjustments for: Non -Cash Items / Other Investment or Financial Items (31.3) (37.3) (25.9) (15.3) (9.6) Operating profit before working capital changes 202.3 166.8 117.7
Slide 34: Thank You!
Thank You! Innova Captab Limited : Investor Relations Advisor : http://www.sgapl.net/images/sgapl_logo.jpg Strategic Growth Advisors Pvt. Ltd. Innova Captab Ltd. CIN - U74140MH2010PTC204285 CIN – L24246MH2005PLC150371 Ms. Shaily Patwa / Mr. Shrikant Sangani Mr. Lokesh Bhasin/ Mr. Ayush Kumar Garg Em